Aldesleukin

{
  "id": "MLC-T-ONC-000365",
  "term": "Aldesleukin",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with melanoma or renal cell carcinoma (a type of kidney cancer) that has spread to other parts of the body. It is also being studied in the treatment of other types of cancer. Aldesleukin is a form of interleukin-2 that is made in the laboratory. Aldesleukin increases the activity and growth of white blood cells called T lymphocytes and B lymphocytes, which may help the immune system kill cancer cells. Aldesleukin is a type of cytokine and a type of immunomodulating agent. Also called Proleukin and recombinant human interleukin-2.",
    "A recombinant analog of the endogenous cytokine interleukin-2 (IL-2) with immunoregulatory and antineoplastic activities. Aldesleukin binds to and activates the IL-2 receptor, followed by heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains; activation of the tyrosine kinase Jak3; and phosphorylation of tyrosine residues on the IL-2R beta chain, resulting in an activated receptor complex. Various cytoplasmic signaling molecules are recruited to the activated receptor complex and become substrates for regulatory enzymes that are associated with the receptor complex. This agent enhances lymphocyte mitogenesis; stimulates long-term growth of human IL-2 dependent cell lines; enhances lymphocyte cytotoxicity; induces lymphokine-activated killer (LAK) cell and natural killer (NK) cell activities; and induces expression of interferon-gamma. Aldesleukin may induce T cell-mediated tumor regression in some tumor types."
  ],
  "abbreviation": "r-serHuIL-2",
  "synonyms": [
    "Proleukin",
    "recombinant human interleukin-2",
    "recombinant human IL-2"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/aldesleukin/"
}